1-{4-[2-((S)-1-Amino-3-methyl-butyl)-4-trifluoromethyl-phenyl]-piperazin-1-yl}-3-(2-fluoro-phenyl)-propan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-{4-[2-((S)-1-Amino-3-methyl-butyl)-4-trifluoromethyl-phenyl]-piperazin-1-yl}-3-(2-fluoro-phenyl)-propan-1-one
• 英文别名: (S)-1-(4-(2-(1-amino-3-methylbutyl)-4-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(2-fluorophenyl)propan-1-one；1-[4-[2-[(1S)-1-amino-3-methylbutyl]-4-(trifluoromethyl)phenyl]piperazin-1-yl]-3-(2-fluorophenyl)propan-1-one
• 化学式: C₂₅H₃₁F₄N₃O
• 分子量: 465.534
• InChiKey: AKQUFOFELDSFGJ-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-(2-甲酰基-4-(三氟甲基)苯基)哌嗪-1-羧酸叔丁酯 在 盐酸 、 titanium(IV) tetraethanolate 、 三甲基铝 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-{4-[2-((S)-1-Amino-3-methyl-butyl)-4-trifluoromethyl-phenyl]-piperazin-1-yl}-3-(2-fluoro-phenyl)-propan-1-one
  参考文献：
  名称：

  Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor

  摘要：

  A series of 3-arylpropionylpiperazines were synthesized as antagonists of the melanocortin-4 receptor. Their potency was found to be increased by replacing the alpha-methyl substituent of the initial lead 11 with a larger s-Bu or i-Bu group. Further potency enhancement was observed when a glycine or beta-alanine was incorporated onto the benzylamine. Some compounds demonstrated good potency, moderate selectivity, and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.088

文献信息

• Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor
  作者：Wanlong Jiang、Fabio C. Tucci、Caroline W. Chen、Melissa Arellano、Joe A. Tran、Nicole S. White、Dragan Marinkovic、Joseph Pontillo、Beth A. Fleck、Jenny Wen、John Saunders、Ajay Madan、Alan C. Foster、Chen Chen

  DOI：10.1016/j.bmcl.2006.05.088

  日期：2006.9

  A series of 3-arylpropionylpiperazines were synthesized as antagonists of the melanocortin-4 receptor. Their potency was found to be increased by replacing the alpha-methyl substituent of the initial lead 11 with a larger s-Bu or i-Bu group. Further potency enhancement was observed when a glycine or beta-alanine was incorporated onto the benzylamine. Some compounds demonstrated good potency, moderate selectivity, and oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.